AB&B Bio-Tech Co., Ltd. JS (AB&B Bio-Tech-B (02627)) announced that the U.S. Food and Drug Administration approved the Investigational New Drug application for its self-developed mRNA mpox vaccine candidate. According to official information, preclinical results showed that this candidate elicited higher levels of neutralizing antibodies against mpox than the live-attenuated variola virus vaccine commonly used in China and displayed broad-spectrum cross-reactivity against orthopoxvirus antigens.

The vaccine’s immunogenicity profile was noted to be particularly suited for immunocompromised individuals, including those who are HIV-positive. The new vaccine candidate is the first of its kind in China and the third worldwide to obtain this IND approval in the United States.

Additionally, the company focuses on developing both innovative and improved vaccines that target global trends in infectious diseases. Its product pipeline includes quadrivalent and trivalent subunit influenza vaccines, a lyophilized human rabies vaccine candidate, and other vaccine candidates for international and domestic markets.